Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma DOI Open Access
Eisuke Ueshima, Keitaro Sofue,

Shohei Komatsu

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 948 - 948

Published: March 11, 2025

Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of immunoscore linked dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies counted positive cells in invasive margin (IM) central tumor (CT), converting them an 0 4 points. assessed CECT findings obtained from 96 patients who underwent hepatectomy HCC evaluated relationship between immunoscores. For validation, we effects on 81 nodules using Response Evaluation Criteria Solid Tumors another cohort 41 received combined atezolizumab bevacizumab (n = 27) durvalumab tremelizumab 14). Results: HCCs peritumoral enhancement arterial phase (p < 0.001) rim APHE 0.009) were associated univariate linear regression analysis 0.004) multivariate analysis. The time nodular progression was significantly longer than that without this feature 0.001). Conclusions: identified as a noninvasive biomarker predict immune-inflamed high tendency. These most likely respond immunotherapy.

Language: Английский

Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma DOI Open Access
Eisuke Ueshima, Keitaro Sofue,

Shohei Komatsu

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 948 - 948

Published: March 11, 2025

Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of immunoscore linked dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies counted positive cells in invasive margin (IM) central tumor (CT), converting them an 0 4 points. assessed CECT findings obtained from 96 patients who underwent hepatectomy HCC evaluated relationship between immunoscores. For validation, we effects on 81 nodules using Response Evaluation Criteria Solid Tumors another cohort 41 received combined atezolizumab bevacizumab (n = 27) durvalumab tremelizumab 14). Results: HCCs peritumoral enhancement arterial phase (p < 0.001) rim APHE 0.009) were associated univariate linear regression analysis 0.004) multivariate analysis. The time nodular progression was significantly longer than that without this feature 0.001). Conclusions: identified as a noninvasive biomarker predict immune-inflamed high tendency. These most likely respond immunotherapy.

Language: Английский

Citations

0